Floatz logo

Olvimulogene Nanivacirepvec

Platinum-refractory Ovarian Cancer

Genelux Corporationgene_therapyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Platinum-refractory Ovarian Cancer cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Olvimulogene Nanivacirepvec is also rated in:

ovarian endometrioid adenocarcinomaDormant
B
Indicative ·
60 / 100
View asset →
ovarian serous adenocarcinomaDormant
B
Indicative ·
60 / 100
View asset →
Ovarian Clear Cell CarcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →